BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17450046)

  • 1. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.
    Armenteros JL; Lewis JE; Davalos M
    J Am Acad Child Adolesc Psychiatry; 2007 May; 46(5):558-565. PubMed ID: 17450046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.
    Farmer CA; Epstein JN; Findling RL; Gadow KD; Arnold LE; Kipp H; Kolko DJ; Butter E; Schneider J; Bukstein OG; McNamara NK; Molina BS; Aman MG
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):117-124. PubMed ID: 27348211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
    Arnold LE; Gadow KD; Farmer CA; Findling RL; Bukstein O; Molina BS; Brown NV; Li X; Rundberg-Rivera EV; Bangalore S; Buchan-Page K; Hurt EA; Rice R; McNamara NK; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):203-12. PubMed ID: 25885010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders.
    Findling RL; Townsend L; Brown NV; Arnold LE; Gadow KD; Kolko DJ; McNamara NK; Gary DS; Kaplin DB; Farmer CA; Kipp H; Williams C; Butter EM; Bukstein OG; Rice R; Buchan-Page K; Molina BS; Aman MG
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):52-65. PubMed ID: 28212067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
    Masi G; Manfredi A; Nieri G; Muratori P; Pfanner C; Milone A
    J Clin Psychopharmacol; 2017 Oct; 37(5):590-594. PubMed ID: 28806385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.
    Rundberg-Rivera EV; Townsend LD; Schneider J; Farmer CA; Molina BB; Findling RL; Gadow KD; Bukstein OG; Arnold LE; Kolko DJ; Buchan-Page KA; McNamara NK; Michel C; Austin A; Kipp H; Rice RR; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):225-33. PubMed ID: 25885012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.
    Farmer CA; Brown NV; Gadow KD; Arnold LE; Kolko DG; Findling RL; Molina BS; Buchan-Page KA; Rice RR; Bangalore SS; Bukstein O; Rundberg-Rivera EV; McNamara N; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):213-24. PubMed ID: 25885011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?
    Aman MG; Bukstein OG; Gadow KD; Arnold LE; Molina BS; McNamara NK; Rundberg-Rivera EV; Li X; Kipp H; Schneider J; Butter EM; Baker J; Sprafkin J; Rice RR; Bangalore SS; Farmer CA; Austin AB; Buchan-Page KA; Brown NV; Hurt EA; Grondhuis SN; Findling RL
    J Am Acad Child Adolesc Psychiatry; 2014 Jan; 53(1):47-60.e1. PubMed ID: 24342385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
    Joseph HM; Farmer C; Kipp H; Kolko D; Aman M; McGinley J; Arnold LE; Gadow KD; Findling RL; Molina BSG
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):90-99. PubMed ID: 30592635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Not just another antipsychotic-for-conduct-problems trial.
    Blader JC
    J Am Acad Child Adolesc Psychiatry; 2014 Jan; 53(1):17-20. PubMed ID: 24342382
    [No Abstract]   [Full Text] [Related]  

  • 14. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.
    Gadow KD; Arnold LE; Molina BS; Findling RL; Bukstein OG; Brown NV; McNamara NK; Rundberg-Rivera EV; Li X; Kipp HL; Schneider J; Farmer CA; Baker JL; Sprafkin J; Rice RR; Bangalore SS; Butter EM; Buchan-Page KA; Hurt EA; Austin AB; Grondhuis SN; Aman MG
    J Am Acad Child Adolesc Psychiatry; 2014 Sep; 53(9):948-959.e1. PubMed ID: 25151418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation.
    Correia Filho AG; Bodanese R; Silva TL; Alvares JP; Aman M; Rohde LA
    J Am Acad Child Adolesc Psychiatry; 2005 Aug; 44(8):748-55. PubMed ID: 16034276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder.
    Gorman EB; Klorman R; Thatcher JE; Borgstedt AD
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):808-16. PubMed ID: 16832317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].
    Akhondzadeh S; Mohammadi MR; Khademi M
    BMC Psychiatry; 2004 Apr; 4():9. PubMed ID: 15070418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
    Turgay A; Binder C; Snyder R; Fisman S
    Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.